Chemistry Reference
In-Depth Information
Fig. 8 In vivo
biodistribution of
14
C-
labeled HPPH-3Gd(III)
DTPA in Ward colon
tumors (3 rats/group). At
24, 48 after injection, 3 rats/
time point were sacrificed.
Preferable uptake of the
conjugate in the tumor was
seen at 24 and 48 h after
compared to most normal
tissues
Fig. 9 In vivo PDT
efficacy of HPPH-3Gd(III)
DTPA in (a) C3H mice
bearing RIF tumors and
(b) BALB/c mice bearing
Colon26 tumors at an
imaging dose (10 mmol/kg).
Mice were irradiated with a
laser light (665 nm,
70 J/cm
2
, 70 mW/cm
2
)
and the tumor size was
measured daily
their target specificity with similar lipophilicity. For example, glucose and galac-
tose analogs showed similar overall lipophilicity, but a significant difference in
PDT efficacy and tumor specificity. The galactose and glucose conjugates were also
evaluated for in vivo imaging and PDT. Among the analogs tested for PET imaging,
the noncarbohydrate and the galactose analogs showed higher tumor imaging.
However, the galactose analog retained in tumor for a longer time, but it also
showed a significantly high uptake in liver. On the basis of detailed in vivo studies
for cancer imaging (PET/fluorescence and PET) and photodynamic therapy, the
noncarbohydrate photosensitizer in combination of
124
I-radioactive and
nonradioactive (
127
I-) analogs proved to be an excellent candidate for cancer
diagnosis (Fig.
10
) and fluorescence image-guided therapy. Efforts are under way
to advance this product to phase I human clinical trials.
3 Multimodality Agents: Advantages of Nanoparticles
Although nanoplatforms and nanovectors (i.e., a nanoplatform that delivers a
therapeutic or imaging agent) for biomedical applications are still evolving, they
show enormous promise for cancer diagnosis and therapy.
